Table 1.
Background baseline characteristics
| Total | McKeown | Ivor Lewis | P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N | 204 | 89 | 115 | ||||||
| Age (median (IQR), y) | 65 | (58–71) | 64 | (59.5–72) | 67 | (56–69) | 0.011 | ||
| Gender | Male | 159 | (77.9) | 64 | (71.9) | 95 | (82.6) | 0.068 | |
| Tumor location | Distal esophagus | 173 | (84.8) | 75 | (84.3) | 98 | (85.2) | 0.852 | |
| GEJ | 31 | (15.2) | 14 | (15.7) | 17 | (14.8) | |||
| Comorbidity | No | 103 | (50.5) | 50 | (47.2) | 61 | (53.0) | 0.407 | |
| Cardiovascular | 86 | (42.2) | 39 | (43.8) | 47 | (40.9) | 0.672 | ||
| Pulmonal | 14 | (6.9) | 8 | (9.0) | 6 | (5.2) | 0.291 | ||
| Metabolic | 22 | (10.8) | 10 | (11.2) | 12 | (10.4) | 0.855 | ||
| ASA classification | 1 | 63 | (30.9) | 23 | (25.8) | 40 | (34.8) | 0.240 | |
| 2 | 99 | (48.5) | 49 | (55.1) | 50 | (43.5) | |||
| 3 | 42 | (20.6) | 17 | (19.1) | 25 | (21.7) | |||
| Neoadjuvant therapy | No | 34 | (16.7) | 20 | (22.5) | 14 | (12.2) | 0.059 | |
| Yes | Chemotherapy | 5 | (2.5) | 1 | (1.1) | 4 | (3.5) | 0.649 | |
| Chemoradiotherapy | 165 | (80.9) | 68 | (76.4) | 97 | (84.3) | |||
| Approach | Open | 18 | (8.8) | 14 | (15.7) | 4 | (3.5) | 0.002 | |
| Minimally invasive | 186 | (91.2) | 75 | (84.3) | 111 | (96.5) | |||
| cT | T0 | 6 | (2.9) | 5 | (5.6) | 1 | (0.9) | 0.298 | |
| T1 | 29 | (14.2) | 14 | (15.7) | 15 | (13.0) | |||
| T2 | 53 | (26.0) | 24 | (27.0) | 29 | (25.2) | |||
| T3 | 114 | (55.9) | 44 | (49.4) | 70 | (60.9) | |||
| T4 | 2 | (1.0) | 2 | (2.2) | 0 | 0 | |||
| cN | N0 | 90 | (44.1) | 38 | (42.7) | 52 | (45.2) | 0.680 | |
| N1 | 76 | (37.3) | 32 | (36.0) | 44 | (38.3) | |||
| N2 | 35 | (17.2) | 19 | (21.3) | 16 | (13.9) | |||
| N3 | 3 | (1.5) | 0 | 0 | 3 | (2.6) | |||
| cM | cM0 | 204 | (100) | 89 | (100) | 115 | (100) | 1.000 | |
| Adjuvant therapy | No | 179 | (87.7) | 86 | (96.6) | 93 | (80.9) | 0.001 | |
| Yes | Chemotherapy | 22 | (10.8) | 2 | (2.2) | 20 | (17.4) | 0.330 | |
| Chemoradiotherapy | 3 | (1.5) | 1 | (1.1) | 1 | (1.7) | |||
| Histologic type | Adenocarcinoma | 164 | (80.4) | 60 | (67.4) | 103 | (89.6) | <0.001 | |
| Squamous cell carcinoma | 33 | (16.2) | 24 | (27.0) | 9 | (7.8) | |||
| Other | 7 | (3.4) | 4 | (4.5) | 3 | (2.6) | |||
| pT | T0 | 55 | (27.0) | 23 | (25.8) | 32 | (27.8) | 0.491 | |
| T1 | 55 | (27.0) | 28 | (31.5) | 27 | (23.5) | |||
| T2 | 25 | (12.3) | 12 | (13.5) | 13 | (11.3) | |||
| T3 | 69 | (33.8) | 26 | (29.2) | 43 | (37.4) | |||
| T4 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| pN | N0 | 140 | (68.6) | 64 | (71.9) | 76 | (66.1) | 0.487 | |
| N1 | 45 | (22.1) | 19 | (21.3) | 26 | (22.6) | |||
| N2 | 9 | (4.4) | 4 | (4.5) | 5 | (4.3) | |||
| N3 | 10 | (4.9) | 2 | (2.2) | 8 | (7.0) | |||
| c/pM | cM1 | 2 | (1.0) | 1 | (0.9) | 1 | (1.1) | 1.000 | |
| Radicality | R0 | 202 | (99.0) | 89 | (100) | 113 | (98.3) | 1.000 | |
| R1 | 2 | (1.0) | 0 | 0 | 2 | (1.7) | |||
| Lymph nodes (median (IQR)) | 26 | (20–37) | 23 | (17–31) | 31 | (22–39) | <0.001 | ||
| Lymph node metastases (median (IQR)) | 0 | (0–1) | 0 | (0–1) | 0 | (0–1) | 0.378 | ||
| Tumor response after neoadjuvant therapy | 1 | 45 | (26.5) | 17 | (24.6) | 28 | (27.7) | 0.144 | |
| 2 | 47 | (27.6) | 25 | (36.2) | 22 | (21.8) | |||
| 3 | 42 | (24,7) | 14 | (20.3) | 28 | (27.7) | |||
| 4 | 30 | (17.6) | 11 | (15.9) | 19 | (18.8) | |||
| 5 | 6 | (3.5) | 2 | (2.9) | 4 | (4.0) | |||
n (%) unless otherwise indicated; y, years; IQR, interquartile range. TNM staging classification (AJCC 8th edition). Bold values are significant.